Home/Filings/4/0000950170-24-023302
4//SEC Filing

Murdock Hunter R. 4

Accession 0000950170-24-023302

CIK 0001579428other

Filed

Feb 28, 7:00 PM ET

Accepted

Feb 29, 5:39 PM ET

Size

8.1 KB

Accession

0000950170-24-023302

Insider Transaction Report

Form 4
Period: 2024-02-27
Murdock Hunter R.
General Counsel
Transactions
  • Award

    Employee Stock Option (Right to Buy)

    2024-02-27+23,59323,593 total
    Exercise: $84.00Exp: 2034-02-26Common Stock (23,593 underlying)
  • Award

    Restricted Stock Units

    2024-02-27+12,95612,956 total
    Common Stock (12,956 underlying)
Footnotes (3)
  • [F1]The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on February 27, 2028.
  • [F2]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
  • [F3]25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on February 27, 2028. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant.

Documents

1 file

Issuer

Axsome Therapeutics, Inc.

CIK 0001579428

Entity typeother

Related Parties

1
  • filerCIK 0001934008

Filing Metadata

Form type
4
Filed
Feb 28, 7:00 PM ET
Accepted
Feb 29, 5:39 PM ET
Size
8.1 KB